Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections

Expert Opinion on Investigational Drugs

Volumn 24, Issue 9, 2015, Pages 1261-1273

  Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

avibactam; ceftazidime; intra abdominal infections; urinary tract infections; lactamases

Indexed keywords

2 HYDROXY 3 (2 THIENYLACETAMIDO) 1,5,2 DIOXABOREPANE 7 ACETIC ACID; ANTIBIOTIC AGENT; AVIBACTAM; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CARBAPENEM; CARBAPENEMASE; CEFEPIME; CEFTAZIDIME; CEFTOLOZANE PLUS TAZOBACTAM; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CREATININE; EXTENDED SPECTRUM BETA LACTAMASE; LEVOFLOXACIN; LINEZOLID; LIVER ENZYME; MEROPENEM; METRONIDAZOLE; NEW DRUG; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RELEBACTAM; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE;

ABDOMINAL INFECTION; ABDOMINAL PAIN; ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANXIETY DISORDER; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIUM ISOLATE; CATHETER INFECTION; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; ENTEROBACTER; ENTEROBACTERIACEAE; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FOOD AND DRUG ADMINISTRATION; GRAM NEGATIVE BACTERIUM; HEADACHE; HOSPITAL READMISSION; HUMAN; HYPERTRANSAMINASEMIA; INAPPROPRIATE PRESCRIBING; KIDNEY FAILURE; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA AND VOMITING; NONHUMAN; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSEUDOMONAS AERUGINOSA; REVIEW; TREATMENT OUTCOME; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; ANIMAL; DRUG EFFECTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; INTRAABDOMINAL INFECTIONS; MICROBIOLOGY; URINARY TRACT INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAM RESISTANCE; BETA-LACTAMASE INHIBITORS; CEFTAZIDIME; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTRAABDOMINAL INFECTIONS; URINARY TRACT INFECTIONS;

EID: 84939799864     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.1062873     Document Type: Review

References (69)

1. Ambler RP. The structure of b-lactamases. Philos Trans R Soc Lond B Biol Sci 1980;289:321-31
2. Bush K, Jacoby GA. Updated functional classification of b-lactamases. Antimicrob Agents Chemother 2010;54:969-76
3. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for b-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-33
4. Paterson DL, Bonomo RA. Extended-spectrum b-lactamases: a clinical update. Clin Microbiol Rev 2005;18:657-86
5. Falagas ME, Karageorgopoulos DE. Extended-spectrum b-lactamase-producing organisms. J Hosp Infect 2009;73:345-54
6. Jacoby GA. AmpC b-lactamases. Clin Microbiol Rev 2009;22:161-82
7. Rolain JM, Cornaglia G. Carbapenemases in Enterobacteriaceae: the magnitude of a worldwide concern. Clin Microbiol Infect 2014;20:819-20
8. Perez F, van Duin D. Carbapenem-resistant Enterobacteriaceae: A menace to our most vulnerable patients. Cleve Clin J Med 2013;80:224-33
9. Dortet L, Poirel L, Nordmann P. Worldwide dissemination of the NDMtype carbapenemases in Gram-negative bacteria. BioMed Res Int 2014;2014:249856
10. Strateva T, Yordanov D. Pseudomonas aeruginosa-A phenomenon of bacterial resistance. J Med Microbiol 2009;58:1133-48
11. Maragakis LL, Perl TM. Acinetobacter baumannii: Epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008;46:1254-63
12. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-Abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010;50:133-64
13. Chen YH, Hsueh PR. Changing bacteriology of abdominal and surgical sepsis. Curr Opin Infect Dis 2012;25:590-5
14. Morrissey I, Hackel M, Badal R, et al. A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals 2013;6:1335-46
15. Hoban DJ, Badal R, Bouchillon S, et al. In vitro susceptibility and distribution of b-lactamases in Enterobacteriaceae causing intra-Abdominal infections in North America 2010-2011. Diagn Microbiol Infect Dis 2014;79:367-72
16. Babinchak T, Badal R, Hoban D, et al. Trends in susceptibility of selected gram-negative bacilli isolated from intraabdominal infections in North America: SMART 2005-2010. Diagn Microbiol Infect Dis 2013;76:379-81
17. Lagace-Wiens PRS, Adam HJ, Low DE, et al. Trends in antibiotic resistance over time among pathogens from Canadian hospitals: results of the CANWARD study 2007-11. J Antimicrob Chemother 2013;68(Suppl 1):i23-9
18. Flamm RK, Farrell DJ, Sader HS, et al. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intraabdominal and urinary tract infections in US medical centres (2012). J Antimicrob Chemother 2014;69:1589-98
19. Montravers P, Gauzit R, Muller C, et al. Emergence of antibiotic-resistance bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996;23:486-94
20. Mosdell DM, Morris DM, Voltura A, et al. Antibiotic treatment for surgical peritonitis. Ann Surg 1991;214:543-9
21. Mazzulli T. Diagnosis and management of simple and complicated urinary tract infections (UTIs). Can J Urol 2012;19(Suppl 1):42-8
22. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-Associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2010;50:625-63
23. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-Associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013;34:1-14
24. Sader HS, Flamm RK, Jones RN. Frequency of occurrence and antimicrobial susceptibility of Gramnegative bacteremia isolates in patients with urinary tract infection: results from United States and European hospitals (2009-2011). J Chemother 2014;26:133-8
25. Bouchillon S, Hoban DJ, Badal R, et al. Fluoroquinolone resistance among Gramnegative urinary tract pathogens: global SMART program results, 2009-2010. Open Microbiol J 2012;6:74-8
26. Esparcia A, Artero A, Eiros JM, et al. Influence of inadequate antimicrobial therapy on prognosis in elderly patients with severe urinary tract infections. Eur J Intern Med 2014;25:523-7
27. MacVane SH, Tuttle LO, Nicolau DP. Impact of extended-spectrum b-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infections. J Hosp Med 2014;9:232-8
28. MacVane SH, Tuttle LO, Nicolau DP. Demography and burden of care associated with patients readmitted for urinary tract infection. J Microbiol Immunol Infect 2014. [Epub ahead of print]
29. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: No ESKAPE! an update from the infectious diseases society of america. Clin Infect Dis 2009;48:1-12
30. Appelbaum PC. 2012 and beyond: potential for the start of a second preantibiotic era? J Antimicrob Chemother 2012;67:2062-8
31. Hong M-C, Hsu DI, Bounthavong M. Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and b-lactamase-inhibitor combination. Infect Drug Res 2013;6:215-23
32. Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 2013;68:2286-90
33. Livermore DM, Mushtaq S. Activity of biapenem (RPX2003) combined with the boronate b-lactamase inhibitor RPX7009 against carbapenems-resistant Enterobacteriaceae. J Antimicrob Chemother 2013;68:1825-31
34. Livermore DM, Mushtaq S, Warner M, et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2011;55:390-4
35. Sader HS, Farrell DJ, Flamm RK, et al. Antimicrobial susceptibility of Gramnegative organisms isolates from patients hospitalized with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents 2014;43:328-34
36. Ehmann DE, Jahić H, Ross PL, et al. Avibactam is a covalent, reversible, non-b-lactam b-lactamase inhibitor. Proc Natl Acad Sci USA 2012;109:11663-8
37. Ehmann DE, Jahić H, Ross PL, et al. Kinetics of avibactam inhibition against Class A, C, and D b-lactamases. J Biol Chem 2013;288:27960-71
38. Lagace-Wiens PRS, Tailor F, Simner P, et al. Activity of NXL 104 in combination with b-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing Class A extended-spectrum b-lactamases and Class C b-lactamases. Antimicrob Agents Chemother 2011;55:2434-7
39. Levasseur P, Girard A-M, Claudon M, et al. In vitro antibacterial activity of the ceftazidime-Avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2012;56:1606-8
40. Berkhout J, Melchers MJ, van Mil AC, et al. In vitro activity of ceftazidimeavibactam combination in in vitro checkerboard assays. Antimicrob Agents Chemother 2015;59:1138-44
41. Sader HS, Castanheira M, Flamm RK, et al. Antimicrobial activity of ceftazidime-Avibactam against gramnegative organisms collected from US medical centers in 2012. Antimicrob Agents Chemother 2014;58:1684-92
42. Wang X, Zhang F, Zhao C, et al. In vitro activities of ceftazidime-Avibactam and aztreonam-Avibactam against 372 gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob Agents Chemother 2014;58:1774-8
43. Aktas Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL 104) in combination with b-lactams against gram-negative bacteria, including OXA-48 b-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 2012;39:86-9
44. Flamm RK, Stone GG, Sader HS, et al. Avibactam reverts the ceftazidime MIC90 of European gram-negative bacterial clinical isolates to the epidemiological cut-off value. J Chemother 2014;26:333-8
45. Keepers TR, Gomez M, Celeri C, et al. Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-Avibactam against b-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2014;58:5297-305
46. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of b-lactams, glycopeptides, and linezolid. Infect Dis Clin N Am 2003;17:479-501
47. Muller AE, Punt N, Mouton JW. Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother 2013;68:900-6
48. MacVane SH, Kuti JL, Nicolau DP. Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-Associated pneumonia. Antimicrob Agents Chemother 2014;58:1359-64
49. Coleman K, Levasseur P, Girard AM, et al. Activities of ceftazidime and avibactam against b-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model. Antimicrob Agents Chemother 2014;58:3366-72
50. Nichols W, Levasseur P, Li J, et al. A threshold concentration of avibactam (AVI) during the pharmacokinetic decline phase, below which b-lactamase inhibition in Enterobacteriaceae becomes ineffective. [abstract A-1760]. Paper presented at 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy9-12 September, 2012; San Francisco, California, USA
51. Berkhout J, Melchers MJ, Van Mill CH, et al. Pharmacodynamics of ceftazidime and avibactam in a neutropenic mouse lung model. [abstract A-1022]. Paper presented at 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 10-13 September, 2013; Denver, Colorado, USA
52. Berkhout J, Melchers MJ, Van Mill CH, et al. Exposure response relationship of ceftazidime and avibactam in a neutropenic thigh model. [abstract A-1023]. Paper presented at 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 10-13 September, 2013; Denver, Colorado, USA
53. Li J, Knebel W, Riggs M, et al. Population pharmacokinetic modeling of ceftazidime (CAZ) and avibactam (AVI) in healthy volunteers and patients with complicated intra-Abdominal infection (cIAIs). [abstract A-634]. Paper presented at 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 9-12 September, 2012; San Francisco, California, USA
54. Edeki T, Armstrong J, Li J. Pharmacokinetics of avibactam (AVI) and ceftazidime (CAZ) following separate or combined administration in healthy volunteers. [abstract A-1019]. Paper presented at 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 10-13 September, 2013; Denver, Colorado, USA
55. Merdjan H, Tarral A, Haazen W, et al. Pharmacokinetics and tolerability of NXL 104 in normal subjects and patients with varying degrees of renal insufficiency [abstract P1598]. Paper presented at 20th European Congress of Clinical Microbiology and Infectious Diseases; 10-13 April, 2010; Vienna, Austria
56. Li J, Zhou D, Nichols W, et al. Evaluation of ceftazidime-Avibactam (CAZ-AVI) dose regimens for phase III study in patients with different renal function. [abstract A-635]. Paper presented at 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 9-12 September, 2012; San Francisco, California, USA
57. FORTAZ. Prescribing Information for Ceftazidime injection. GlaxoSmithKline, LLC; Research Triangle Park, NC: 2010
58. Merdjan H, Rangaraju M, Tarral A. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebocontrolled studies. Clin Drug Invest 2015;35:307-17
59. Endimiani A, Hujer KM, Hujer AM, et al. Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2011;55:82-5
60. Levasseur P, Girard A-M, Lavallade L, et al. Efficacy of a ceftazidime-Avibactam combination in a murine model of septicemia caused by Enterobacteriaceae species producing AmpC or extendedspectrum b-lactamases. Antimicrob Agents Chemother 2014;58:6490-5
61. Crandon JL, Schuck VJ, Banevicius MA, et al. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-Avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2012;56:6137-46
62. MacVane SH, Crandon JL, Nichols WW, et al. In vivo efficacy of humanized exposures of ceftazidimeavibactam in comparison with ceftazidime against contemporary Enterobacteriaceae isolates. Antimicrob Agents Chemother 2014;58:6913-19
63. Housman ST, Crandon JL, Nichols WW, et al. Efficacies of ceftazidime-Avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model. Antimicrob Agents Chemother 2014;58:1365-71
64. Dallow J, Otterson LG, Huband MD, et al. Microbiological interaction studies between ceftazidime-Avibactam and lung surfactant and between ceftazidimeavibactam and antibacterial agents of other classes. Int J Antimicrob Agents 2014;44:552-6
65. Lucasti C, Popescu I, Ramesh MK, et al. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-Abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. J Antimicrob Chemother 2013;68:1183-92
66. Vazquez JA, González Patzán LD, Stricklin D, et al. Efficacy and safety of ceftazidime-Avibactam versus imipenemcilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigatorblinded, randomized study. Curr Med Res Opin 2012;28:1921-31
67. Mazuski JE, Gasnik L, Armstrong J, et al. Efficacy and safety of ceftazidimeavibactam plus metronidazole versus meropenem in the treatment of complicated intra-Abdominal infection-results from a Phase III program [abstract 0191]. Paper presented at 25th European Congress of Clinical Microbiology and Infectious Diseases; 25-28 April, 2015; Copenhagen, Denmark
68. Carmeli Y, Armstrong J, Laud P, et al. Efficacy and safety of ceftazidimeavibactam and best available therapy in the treatment of ceftazidime-resistant infections-results from a Phase III study [abstract LBEV0061b]. Paper presented at 25th European Congress of Clinical Microbiology and Infectious Diseases; 25-28 April, 2015; Copenhagen, Denmark
69. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement. M100-S20 Wayne; PA, USA: 2010